Showing results (21-30 of 152) with videos related to
Sort By:
Pageof 16
Cancers|June 2, 2021
Breaching the Blood-Brain Tumor Barrier for Tumor TherapyFabrizio Marcucci, Angelo Corti, Andrés J M FerreriRegulatory Peptides|May 5, 2005
Inhibitory influence of chromogranin A N-terminal fragment (vasostatin-1) on the spontaneous contractions of rat proximal colonAntonella Amato, Angelo Corti, Rosa Serio, et al.Journal of Oncology|July 9, 2010
Immunomodulatory Agents with Antivascular Activity in the Treatment of Non-Small Cell Lung Cancer: Focus on TLR9 Agonists, IMiDs and NGR-TNFAngelo Corti, Monica Giovannini, Carmen Belli, et al.International Journal of Cancer|November 1, 2013
Pushing tumor cells towards a malignant phenotype: stimuli from the microenvironment, intercellular communications and alternative roadsFabrizio Marcucci, Matteo Bellone, Carmelo Antonio Caserta, et al.Cancer Research|October 7, 2004
Crucial role for interferon gamma in the synergism between tumor vasculature-targeted tumor necrosis factor alpha (NGR-TNF) and doxorubicinAngelina Sacchi, Anna Gasparri, Flavio Curnis, et al.Pharmaceutics|July 27, 2022
Targeting the Blood-Brain Tumor Barrier with Tumor Necrosis Factor-αAngelo Corti, Teresa Calimeri, Flavio Curnis, et al.Cancer Research|January 28, 2004
Coupling tumor necrosis factor-alpha with alphaV integrin ligands improves its antineoplastic activityFlavio Curnis, Anna Gasparri, Angelina Sacchi, et al.Heart, Lung and Vessels|October 24, 2015
Oral direct thrombin inhibition: a double-edged sword?Gabriele Fragasso, Angelo Corti, Ferdinando Loiacono, et al.Cancer Research|December 6, 2011
Chromogranin A regulates tumor self-seeding and disseminationEleonora Dondossola, Luca Crippa, Barbara Colombo, et al.Biodrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy|June 8, 2013
Peptide-mediated targeting of cytokines to tumor vasculature: the NGR-hTNF exampleAngelo Corti, Flavio Curnis, Gilda Rossoni, et al.Pageof 16